N-terminal pro-B-type natriuretic peptide and inducible ischemia in the heart and soul study

Clinical Cardiology

Volumn 32, Issue 8, 2009, Pages 447-453

  Singh, Harsimran S ^a   Bibbins Domingo, Kirsten ^b   Ali, Sadia ^c   Wu, Alan H B ^b   Schiller, Nelson B ^b,c   Whooley, Mary A ^b,c,d  

^a New York Presbyterian Hospital ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE MARKER; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RISK ASSESSMENT; STRESS ECHOCARDIOGRAPHY; SYSTOLIC DYSFUNCTION; TREADMILL EXERCISE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY, STRESS; EXERCISE TEST; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; OUTPATIENTS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; UP-REGULATION;

EID: 69249118284     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20569     Document Type: Article

References (29)

1. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression ofmyocardial BNPduring evolution of heart failure. Am J Physiol. 1998;274(5 Pt 2): H1684-H1689. (Pubitemid 28257544)
2. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem. 2004;50(9): 1503-1510.
3. Hammerer-Lercher A, Ludwig W, Falkensammer G, et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem. 2004;50(7):1174-1183. (Pubitemid 38828285)
4. Miller WL, Hartman KA, Burritt MF, Burnett JC Jr, Jaffe AS. Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies. Clin Cardiol. 2007;30(5):245-250.
5. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002;105(5):595-601. (Pubitemid 34123434)
6. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996;93(11):1963-1969. (Pubitemid 126424495)
7. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl JMed. 2001;345(14):1014-1021. (Pubitemid 34940793)
8. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110(20):3206-3212. (Pubitemid 39525067)
9. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002;40(3):437-445. (Pubitemid 34833157)
10. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation. 2003;108(24):2987-2992. (Pubitemid 37553567)
11. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl JMed. 2005;352(7):666-675. (Pubitemid 40239214)
12. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843-849. (Pubitemid 43799232)
13. Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004;44(10):1988-1995. (Pubitemid 39473283)
14. Foote RS, Pearlman JD, Siegel AH, Yeo KT. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol. 2004;44(10):1980-1987.
15. Staub D, Jonas N, Zellweger MJ, et al. Use of N-terminal pro-B-type natriuretic peptide to detect myocardial ischemia. Am J Med. 2005;118(11):1287. (Pubitemid 41566533)
16. Weber M, Dill T, Arnold R, et al. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J. 2004;148(4): 612-620. (Pubitemid 39349380)
17. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358-367.
18. Angeja BG, Grossman W. Evaluation and management of diastolic heart failure. Circulation. 2003;107(5):659-663. (Pubitemid 36222587)
19. Bibbins-Domingo K, Gupta R, Na B, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297(2):169-176. (Pubitemid 46089733)
20. Gehi AK, Rumsfeld JS, Liu H, Schiller NB, Whooley MA. Relation of self-reported angina pectoris to inducible myocardial ischemia in patients with known coronary artery disease: the Heart and Soul Study. Am J Cardiol. 2003;92(6):705-707. (Pubitemid 37103024)
21. Karabinos I, Karvouni E, Chiotinis N, et al. Acute changes in N-terminal pro-brain natriuretic peptide induced by dobutamine stress echocardiography. Eur J Echocardiogr. 2007;8(4):265-274. (Pubitemid 46969890)
22. D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther. 2004;101(2): 113-129. (Pubitemid 38167564)
23. Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol. 2007;50(3): 205-214. (Pubitemid 47031568)
24. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47(2): 345-353. (Pubitemid 43063253)
25. Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl. 1999;230:132-142. (Pubitemid 29279366)
26. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362(9380):316-322. (Pubitemid 36936846)
27. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007;49(10):1071-1078. (Pubitemid 46349497)
28. Tang WH, Steinhubl SR, Van Lente F, et al. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. Am Heart J. 2007;153(1): 36-41. (Pubitemid 44880884)
29. Peer A, Falkensammer G, Alber H, et al. Limited utilities of N-terminal pro B-type natriuretic peptide (NT-proBNP) and other newer risk markers compared with traditional risk factors for prediction of significant angiographic lesions in stable coronary artery disease. Heart. 2009;95:297-303.